Haemophilia Centre/Haemostasis Unit, Aghia Sophia Children's Hospital, Athens, Greece.
Haemophilia. 2013 Sep;19(5):706-10. doi: 10.1111/hae.12168. Epub 2013 Apr 22.
Human Leucocyte Antigen (HLA) alleles, cytokine polymorphisms and the type of factor VIII (FVIII) gene mutation are among predisposing factors for inhibitors (inh) development in children with severe haemophilia A (HA). The aim was to investigate the correlations among (i) FVIII gene intron-22 inversion, (ii) HLA alleles and haplotypes and (iii) certain cytokine polymorphisms, with the risk for FVIII inhibitors development in 52 Greek severe HA children, exclusively treated with recombinant concentrates. We performed Long-Range PCR for detection of intron-22 inversion and PCR-SSP, PCR-SSO for genotyping of HLA-A, B, C, DRB1, DQB1 alleles and also for cytokine polymorphisms of TNF-α, TGF-β1, IL-10, IL-6 and IFN-γ. Chi-squared test and Fischer's exact test were used for statistical analysis. A total of 28 children had developed inhibitors (Group I), 71.4% high responding, while 24 had not (Group II). No statistically increased intron-22 inversion prevalence was found in Group I compared with Group II (P = 0.5). Comparison of HLA allele frequencies between the two groups showed statistically significant differences in the following genotypes (i) promoting inhibitors development: DRB101(P = 0.014), DRB101:01(P = 0.011) and DQB105:01 (P = 0.005) and (ii) possibly protecting from inhibitors development: DRB111 (P = 0.011), DRB111:01 (P = 0.031), DQB103 (P = 0.004) and DQB1*03:01 (P = 0.014). Analysis of cytokines revealed a higher incidence of inhibitor detection only in homozygotes of the haplotypes ACC and ATA for IL-10 polymorphisms (P = 0.05). There is evidence that HLA alleles and cytokine polymorphisms play an important role in FVIII inh development. On the contrary, no statistically significant results were obtained for intron-22 inversion and its impact on FVIII inhibitors formation.
人类白细胞抗原(HLA)等位基因、细胞因子多态性以及第八因子(FVIII)基因突变类型是导致严重甲型血友病(HA)患儿产生抑制剂(inh)的易感因素。本研究旨在调查 52 例希腊严重 HA 患儿中 FVIII 基因内含子 22 倒位(i)、HLA 等位基因和单倍型(ii)与某些细胞因子多态性(iii)与 FVIII 抑制剂发展风险之间的相关性,这些患儿均单独接受重组浓缩物治疗。我们采用长距离 PCR 检测内含子 22 倒位,采用 PCR-SSP、PCR-SSO 进行 HLA-A、B、C、DRB1、DQB1 等位基因的基因分型,还进行 TNF-α、TGF-β1、IL-10、IL-6 和 IFN-γ 细胞因子多态性的检测。采用卡方检验和 Fisher 精确检验进行统计学分析。共有 28 例患儿产生了抑制剂(I 组),其中 71.4%为高应答者,而 24 例未产生抑制剂(II 组)。与 II 组相比,I 组的内含子 22 倒位发生率并未显著增加(P=0.5)。两组 HLA 等位基因频率比较显示,以下基因型存在统计学显著差异(i)促进抑制剂的产生:DRB101(P=0.014)、DRB101:01(P=0.011)和 DQB105:01(P=0.005),以及(ii)可能抑制抑制剂的产生:DRB111(P=0.011)、DRB111:01(P=0.031)、DQB103(P=0.004)和 DQB1*03:01(P=0.014)。细胞因子分析显示,仅在 IL-10 多态性的 ACC 和 ATA 单倍型纯合子中,抑制剂的检出率更高(P=0.05)。有证据表明,HLA 等位基因和细胞因子多态性在 FVIII inh 的发展中起着重要作用。相反,对于内含子 22 倒位及其对 FVIII 抑制剂形成的影响,并未得到统计学显著结果。